Prostate-specific Antigen Decline After 4 Weeks of Treatment with Abiraterone Acetate and Overall Survival in Patients with Metastatic Castration-resistant Prostate Cancer

European Urology

Volumn 70, Issue 5, 2016, Pages 724-731

  Rescigno, Pasquale ^a   Lorente, David ^a   Bianchini, Diletta ^a   Ferraldeschi, Roberta ^a   Kolinsky, Michael P ^a   Sideris, Spyridon ^a   Zafeiriou, Zafeiris ^a   Sumanasuriya, Semini ^a   Smith, Alan D ^a   Mehra, Niven ^a   Jayaram, Anuradha ^a   Perez Lopez, Raquel ^a   Mateo, Joaquin ^a   Parker, Chris ^a   Dearnaley, David P ^a   Tunariu, Nina ^a   Reid, Alison ^a   Attard, Gerhardt ^a   de Bono, Johann S ^a  

^a INSTITUTE OF CANCER RESEARCH   (United Kingdom)

Author keywords

Abiraterone acetate; Metastatic castration resistant prostate cancer; Prostate specific antigen

Indexed keywords

ABIRATERONE ACETATE; DOCETAXEL; PROSTATE SPECIFIC ANTIGEN; ANTINEOPLASTIC AGENT; TAXOID;

ARTICLE; CANCER CHEMOTHERAPY; CANCER PATIENT; CANCER SURVIVAL; CASTRATION RESISTANT PROSTATE CANCER; HUMAN; MAJOR CLINICAL STUDY; MALE; METASTASIS; OVERALL SURVIVAL; PRIORITY JOURNAL; RETROSPECTIVE STUDY; AGED; BLOOD; CANCER STAGING; DRUG MONITORING; EPIDEMIOLOGY; MIDDLE AGED; MORTALITY; OUTCOME ASSESSMENT; PATHOLOGY; PROCEDURES; REGISTER; STATISTICS; STATISTICS AND NUMERICAL DATA; SURVIVAL ANALYSIS; UNITED KINGDOM;

ABIRATERONE ACETATE; AGED; ANTINEOPLASTIC AGENTS; DRUG MONITORING; HUMANS; MALE; MIDDLE AGED; NEOPLASM METASTASIS; NEOPLASM STAGING; OUTCOME ASSESSMENT (HEALTH CARE); PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS, CASTRATION-RESISTANT; REGISTRIES; STATISTICS AS TOPIC; SURVIVAL ANALYSIS; TAXOIDS; UNITED KINGDOM;

EID: 84959467815     PISSN: 03022838     EISSN: 18737560     Source Type: Journal    
DOI: 10.1016/j.eururo.2016.02.055     Document Type: Article

References (27)

1. [1] Edwards, B.K., Noone, A.M., Mariotto, A.B., et al. Annual Report to the Nation on the status of cancer, 1975–2010, featuring prevalence of comorbidity and impact on survival among persons with lung, colorectal, breast, or prostate cancer. Cancer 120 (2014), 1290–1314.
2. [2] Pound, C.R., Partin, A.W., Eisenberger, M.A., Chan, D.W., Pearson, J.D., Walsh, P.C., Natural history of progression after PSA elevation following radical prostatectomy. JAMA 281 (1999), 1591–1597.
3. [3] Damber, J.E., Endocrine therapy for prostate cancer. Acta Oncol 44 (2005), 605–609.
4. [4] Omlin, A., Pezaro, C., Mukerji, D., et al. Improved survival in a cohort of trial participants with metastatic castration-resistant prostate cancer demonstrates the need for updated prognostic nomograms. Eur Urol 64 (2013), 300–306.
5. [5] Scher, H.I., Heller, G., Clinical states in prostate cancer: toward a dynamic model of disease progression. Urology 55 (2000), 323–327.
6. [6] Carlin, B.I., Andriole, G.L., The natural history, skeletal complications, and management of bone metastases in patients with prostate carcinoma. Cancer 88 (2000), 2989–2994.
7. [7] Scher, H.I., Chung, L.W., Bone metastases: improving the therapeutic index. Semin Oncol 21 (1994), 630–656.
8. [8] Eisenhauer, E.A., Therasse, P., Bogaerts, J., et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 45 (2009), 228–247.
9. [9] Scher, H.I., Halabi, S., Tannock, I., et al. Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group. J Clin Oncol 26 (2008), 1148–1159.
10. [10] Bubley, G.J., Carducci, M., Dahut, W., et al. Eligibility and response guidelines for phase II clinical trials in androgen-independent prostate cancer: recommendations from the Prostate Specific Antigen Working Group. J Clin Oncol 17 (1999), 3461–3467.
11. [11] Kelly, W.K., Scher, H.I., Mazumdar, M., Vlamis, V., Schwartz, M., Fossa, S.D., Prostate-specific antigen as a measure of disease outcome in metastatic hormone-refractory prostate cancer. J Clin Oncol 11 (1993), 607–615.
12. [12] Sridhara, R., Eisenberger, M.A., Sinibaldi, V.J., Reyno, L.M., Egorin, M.J., Evaluation of prostate-specific antigen as a surrogate marker for response of hormone refractory prostate cancer to suramin therapy. J Clin Oncol 13 (1995), 2944–2953.
13. [13] Hussain, M., Goldman, B., Tangen, C., et al. Prostate-specific antigen progression predicts overall survival in patients with metastatic prostate cancer: data from Southwest Oncology Group Trials 9346 (Intergroup Study 0162) and 9916. J Clin Oncol 27 (2009), 2450–2456.
14. [14] Petrylak, D.P., Ankerst, D.P., Jiang, C.S., et al. Evaluation of prostate-specific antigen declines for surrogacy in patients treated on SWOG 99-16. J Natl Cancer Inst 98 (2006), 516–521.
15. [15] Armstrong, A.J., Garrett-Mayer, E., Ou Yang, Y.C., et al. Analysis of prostate-specific antigen decline as a surrogate for overall survival in metastatic hormone-refractory prostate cancer (HRPC): a TAX327 analysis. J Clin Oncol 25 (2007), 3965–3970.
16. [16] Halabi, S., Armstrong, A.J., Sartor, O., et al. Prostate-specific antigen changes as surrogate for overall survival in men with metastatic castration-resistant prostate cancer treated with second line chemotherapy. J Clin Oncol 31 (2013), 3944–3950.
17. [17] Xu, X.S., Ryan, C.J., Stuyckens, K., et al. Correlation between prostate-specific antigen kinetics and overall survival in abiraterone acetate-treated castration-resistant prostate cancer patients. Clin Cancer Res 21 (2015), 3170–3177.
18. [18] Berthold, D.R., Pond, G.R., Roessner, M., et al. Treatment of hormone-refractory prostate cancer with docetaxel or mitoxantrone: relationships between prostate-specific antigen, pain, and quality of life. Response and survival in the TAX-327 study. Clin Cancer Res 14 (2008), 2763–2767.
19. [19] Angelergues, A., Maillet, D., Fléchon, A., et al. Prostate-specific antigen flare induced by cabazitaxel-based chemotherapy in patients with metastatic castration-resistant prostate cancer. Eur J Cancer 50 (2014), 1602–1609.
20. [20] Burgio, S.L., Conteduca, V., Rudnas, B., et al. PSA flare with abiraterone in patients with metastatic castration-resistant prostate cancer. Clin Genitourin Cancer 13 (2015), 39–43.
21. [21] de Bono, J.S., Logothetis, C.J., Molina, A., et al. Abiraterone and increased survival in metastatic prostate cancer. N Engl J Med 364 (2011), 1995–2005.
22. [22] Ryan, C.J., Smith, M.R., Fizazi, K., et al. Abiraterone acetate plus prednisone versus placebo plus prednisone in chemotherapy-naive men with metastatic castration-resistant prostate cancer (COU-AA-302): final overall survival analysis of a randomized, double-blind, placebo-controlled phase 3 study. Lancet Oncol 16 (2015), 152–160.
23. [23] Costelloe, C.M., Chuang, H.H., Madewell, J.E., Ueno, N.T., Cancer response criteria and bone metastases: RECIST 1.1, MDA and PERCIST. J Cancer 1 (2010), 80–92.
24. [24] Morris, M.J., Molina, A., Small, E.J., et al. Radiographic progression-free survival as a response biomarker in metastatic castration-resistant prostate cancer: COU-AA-302 results. J Clin Oncol 21 (2015), 3170–3177.
25. [25] Lorente, D., Ravi, P., Mehra, N., et al. Evaluation of clinical decision-making and use of circulating tumor cells (CTCs) by physician treating castration-resistant prostate cancer (CRPC). Eur J Cancer, 51(Suppl 3), 2015, 2579.
26. [26] Thuret, R., Massard, C., Gross-Goupil, M., et al. The post-chemotherapy PSA surge syndrome. Ann Oncol 19 (2008), 1308–1311.
27. [27] Cramer, S.D., Chang, B.L., Rao, A., et al. Association between genetic polymorphisms in the prostate-specific antigen gene promoter and serum prostate-specific antigen levels. J Natl Cancer Inst 95 (2003), 1044–1053.